HCW Biologics (HCWB) Set to Release Quarterly Earnings on Thursday

HCW Biologics (NASDAQ:HCWB) is expected to be announcing its Q3 2026 resultson Thursday, November 12th. Analysts expect the company to post earnings of ($1.35) per share and revenue of $0.12 million for the quarter. Individuals may visit the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Friday, November 20, 2026 at 4:00 PM ET.

HCW Biologics (NASDAQ:HCWB) last released its earnings results on Friday, August 14th. The company reported ($11.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.98) by ($9.60). HCW Biologics had a negative return on equity of 262.33% and a negative net margin of 83.03%. The firm had revenue of $0.14 million for the quarter, compared to analyst estimates of $0.14 million.

HCW Biologics Stock Down 6.5%

Shares of HCWB opened at $0.95 on Tuesday. HCW Biologics has a 12-month low of $0.95 and a 12-month high of $23.94. The firm has a market capitalization of $2.14 million, a price-to-earnings ratio of -0.03 and a beta of 2.31. The stock’s 50-day moving average price is $1.72 and its 200 day moving average price is $3.97.

Wall Street Analyst Weigh In

HCWB has been the subject of a number of research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of HCW Biologics in a research report on Thursday, October 15th. Wall Street Zen upgraded HCW Biologics from a “sell” rating to a “hold” rating in a research report on Saturday, October 31st. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $30.00.

HCW Biologics Company Profile

HCW Biologics Inc (NASDAQ: HCWB) is a clinical-stage biotechnology company focused on developing immunotherapies for diseases associated with chronic inflammation, immune dysfunction and aging. The company’s research is intended to address conditions in which persistent inflammation contributes to disease progression.

HCW Biologics uses its proprietary TOBI platform to design multifunctional fusion proteins that can target inflammatory pathways and modify immune responses. Its development programs have included HCW9218, an investigational immunotherapy designed to combine immune-stimulating activity with inhibition of transforming growth factor beta, a signaling pathway associated with immune suppression and disease progression.